3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE
Renal Cell Cancer Metastatic
Kidney Cancer Research BureauSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
297 Active assets in the Renal Cell Cancer Metastatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 4 | BBB |
gw786034 Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 4 | BBB |
Belzutifan Vall d'Hebron Institute of Oncology | Phase 3 | BBB |
Alpha-Interferon National Cancer Institute (NCI) | Phase 3 | BBB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →